Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has shared an announcement.
Fusen Pharmaceutical Co., Ltd. reported a significant decline in its financial performance for the first half of 2025, with revenue dropping by 43.3% and gross profit decreasing by 59.4% compared to the same period in 2024. Despite the reduced losses attributable to equity shareholders, the company continues to face challenges in its operations, impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company focuses on the development, production, and sale of pharmaceutical products.
Average Trading Volume: 187,936
Technical Sentiment Signal: Sell
Current Market Cap: HK$250M
Find detailed analytics on 1652 stock on TipRanks’ Stock Analysis page.